Search
Minocycline
go.drugbank.com/drugs/DB01017ApprovedInvestigational[A190723] Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetracyclines.
Products: Nu-minocyclineTisotumab vedotin
go.drugbank.com/drugs/DB16732ApprovedInvestigational[L38429] Tisotumab vedotin-tftv is marketed under the trade name Tivdak as an intravenous injection. On April 29, 2024, tisotumab vedotin was granted full FDA approval. … Each monoclonal antibody molecule carries an average of four MMAE molecules. Tisotumab vedotin is the first TF-directed ADC [A238914] that works by binding to TFs expressed on solid tumours.
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesAsfotase alfa
go.drugbank.com/drugs/DB09105ApprovedInvestigationalAsfotase alfa is a first-in-class bone-targeted enzyme replacement therapy designed to address the underlying cause of hypophosphatasia (HPP)—deficient alkaline phosphatase (ALP). Hypophosphatasia is almost always fatal when severe skele...
Avutometinib
go.drugbank.com/drugs/DB15254ApprovedInvestigationalAvutometinib is a small molecule kinase inhibitor targeted against RAF/MEK1, key regulators of the RAS/RAF/MEK/ERK (MAPK) pathway. The MAPK pathway is implicated in variety of cancers, playing a key role in tumor cell proliferation, diff...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesDeoxycholic acid
go.drugbank.com/drugs/DB03619ApprovedInvestigationalDeoxycholic acid is a a bile acid which emulsifies and solubilizes dietary fats in the intestine, and when injected subcutaneously, it disrupts cell membranes in adipocytes and destroys fat cells in that tissue. In April 2015, deoxycholi...
L-deprenyl-D2 C-11
go.drugbank.com/drugs/DB12650ExperimentalL-deprenyl-D2 C-11 is under investigation in clinical trial NCT01701089 (A Study of RO4602522 in Patients With Alzheimer Disease and in Healthy Volunteers).
Synonyms: (11C)L-deprenyl-D2, L-deprenyl-D2 C-11Canertinib
go.drugbank.com/drugs/DB05424InvestigationalCanertinib is a pan-erbB tyrosine kinase inhibitor which work against esophageal squamous cell carcinoma in vitro and in vivo.
Alglucosidase alfa
go.drugbank.com/drugs/DB01272ApprovedInvestigationalAlglucosidase alfa degrades glycogen by catalyzing the hydrolysis of a-1,4- and a-1,6- glycosidic linkages of lysosomal glycogen.
Categories: Glycogen Storage Disease Type II, Hydrolytic Lysosomal Glycogen-specific EnzymeAlmonertinib
go.drugbank.com/drugs/DB16640ApprovedInvestigationalAlmonertinib is a third-generation EGFR tyrosine kinase inhibitor targeting EGFR-sensitizing and T790M resistance mutations. Unlike other third-generation EGFR TKIs, almonertinib is a pyrimidine-based drug that forms a covalent bond to t...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesAutogene cevumeran
go.drugbank.com/drugs/DB17497InvestigationalAutogene cevumeran is an mRNA-based cancer vaccine targeting an unspecified amount of tumour-associated antigens. It is being investigated for cancers.